|

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

RECRUITINGN/ASponsored by John M. Buatti
Actively Recruiting
PhaseN/A
SponsorJohn M. Buatti
Started2025-10-03
Est. completion2028-10-06
Eligibility
Age21 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07447531

Summary

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Eligibility

Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age \> 21 years
* New pathologically confirmed diagnosis of WHO grade IV malignant glioma
* KPS \> 60
* Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion Criteria:

* History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
* History of iron metabolic disorder such as hemochromatosis
* Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

Conditions2

CancerMalignant Glioma

Locations1 site

University of Iowa Health Care
Iowa City, Iowa, 52245
John Buatti, MD319-356-7590john-buatti@uiowa.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.